Get the Stockscreener App
0.6605
2.90%
-0.0197
Pre-market:
.66
-0.0005
-0.08%
Citius Oncology Inc stock is traded at $0.6605, with a volume of 27,492.
It is down -2.90% in the last 24 hours and down -31.43% over the past month.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
See More
Previous Close:
$0.6802
Open:
$0.6985
24h Volume:
27,492
Relative Volume:
0.21
Market Cap:
$61.41M
Revenue:
$5.61M
Net Income/Loss:
$-42.51M
P/E Ratio:
-1.4174
EPS:
-0.466
Net Cash Flow:
$-16.86M
1W Performance:
-8.24%
1M Performance:
-31.43%
6M Performance:
-38.27%
1Y Performance:
-52.48%
1-Day Range:
$0.6605
$0.7119
1-Week Range:
$0.66
$0.729
52-Week Range:
$0.4912
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.6605 | 63.25M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
CTOR Q1 2026 Earnings: Significant EPS Miss Highlights Continued Investment in PipelineRevenue Surprise History - newsline.com
Citius Oncology (CTOR) Edges Higher as Stock Hovers Near SupportThrowback Trade - newsline.com
CTXR News | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
[EFFECT] CITIUS ONCOLOGY, INC. SEC Filing - Stock Titan
CITIUS ONCOLOGY INC (CTOR) Stock Chart - ChartMill
Citius Oncology (CTOR) stake updated by majority holder Citius Pharma - Stock Titan
Citius Oncology, Inc. Financial Disclosures & SEC Filings - TradingView
[EFFECT] Citius Pharmaceuticals, Inc. SEC Filing - Stock Titan
Citius Oncology Reports Promising Phase 1 Results for LYMPHIR Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Oncology Highlights Promising Phase 1 Results for LYMPHIR® Plus Pembrolizumab in Recurrent Gynecologic Cancers at ASCO 2026 123 - Minichart
Citius Highlights LYMPHIR Combo Data in Gynecologic Cancers - TipRanks
Citius Oncology (CTOR) registers 6.8M warrant shares; highlights Phase 1 LYMPHIR data - Stock Titan
Citius Oncology (NASDAQ: CTOR) highlights Phase 1 LYMPHIR plus pembrolizumab results - Stock Titan
Citius Oncology Highlights Phase 1 Data in an Investigator-Initi - GuruFocus
Citius Oncology (CTXR) Presents Promising Data on LYMPHIR for Gy - GuruFocus
Citius Oncology presents study data on LYMPHIR combination By Investing.com - Investing.com Australia
Citius Oncology presents study data on LYMPHIR combination - Investing.com
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies - PR Newswire
Citius Oncology (NASDAQ: CTOR) clears potential $25M loan conversions and large warrants - Stock Titan
Citius Oncology (Nasdaq: CTOR) registers 32.9M shares tied to warrants and loan conversion - Stock Titan
Citius Oncology (CTOR) Edges Lower as Stock Holds Above Key SupportWave Equality - The Legal Advocate
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue PhaseBook Value Growth - thelegaladvocate.com
Number of shareholders of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combi - GuruFocus
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation - Investing.com Nigeria
Citius Oncology study combining LYMPHIR with pembrolizumab selected for ASCO presentation By Investing.com - Investing.com South Africa
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Citius Oncology Q1 2026 Earnings: Wide EPS Miss Highlights Pre-Revenue ChallengesManagement Guidance Update - newsline.com
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
CTOR Q1 2026 Earnings: Significant EPS Miss Amid Pre-Revenue StageNet Income Trends - The Legal Advocate
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
CTOR Q1 2026 Earnings: Deep Losses and Negative Surprise as Company Remains Pre-RevenueReturn On Equity - thelegaladvocate.com
CTOR Q1 2026 Earnings: Pre-Revenue Biotech Reports Wider-than-Expected Loss; Stock Edges HigherOperating Margin Analysis - The Legal Advocate
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
Citius Pharmaceuticals Q2 2026 Earnings: Revenue Misses $1.7 Million - technotrenz.com
Citius Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) — 10-Q Summary - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Armistice Capital (CTOR) files 9.99% ownership disclosure - Stock Titan
TradingKey - TradingKey
Citius Oncology, Inc. (CTOR) Eps Diluted (TTM) - Zacks Investment Research
Citius Oncology Inc Stock (CTOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):